|
Pharmacoepidemiology & Pharmacogenomics Resources:
Mention of companies, products or services on this Web site is for reference purposes only
and does not constitute endorsement by NCI or the US Government.
Please read our disclaimer.
|
|
Enhancing Development of Genome-Wide Association Methods (ENDGAME)
Description
The NIH consortium on Enhancing Development of Genome-wide Association Methods
(ENDGAME) was formed in 2006 to bring investigators together to develop and test
innovative, informative, and cost-effective study designs and analytical strategies and
tools to perform genome-wide association studies on complex diseases. All strategies and
tools developed through the program will be made available to the scientific community.
The ENDGAME Consortium is led by NHLBI, with additional leadership and participation from
other NIH Institutes including NCI, NIEHS, NHGRI, and NIGMS. Ultimately, the long-term
goal of the consortium is to develop genome-wide association methods that may be used to
(1) identify genetic susceptibility factors to disease, and (2) develop new treatment
strategies to increase therapeutic responsiveness and efficacy. The mission of ENDGAME is
to advance understanding of the utility of genome-wide association in human health and
disease.
ENDGAME is a highly interactive consortium that consists of 11 independently-funded
research groups. Each group is focused on developing specific analytic and computational
methods and strategies, using various phenotype (and some simulated) data.
All ENDGAME groups are expected to advance knowledge of the design and analysis of
genome-wide association as individual groups, and collectively as a consortium. The goals
of ENDGAME include:
- assessing the utility of genome-wide association studies to understand human genetic variation and its role in health and disease;
- developing new, analytic and computational strategies and resources for use by the scientific community to find genes associated with disease;
- identifying approaches for individual disease prevention and treatment, novel therapeutics, and maintenance of health;
- understanding the role of gene-gene and gene environment interactions in disease susceptibility; and
- enabling future molecular-level understanding of fundamental biological processes and discovering approaches to their control.
|
|